The 32 linked references in paper S. Avdeev N., С. Авдеев Н. (2017) “Новые возможности терапии идиопатического легочного фиброза // New abilities in therapy of idiopathic pulmonary fibrosis” / spz:neicon:pulmonology:y:2017:i:4:p:502-514

  1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am. J. Respir. Crit. Care Med. 2011; 183 (3): 788–824. DOI: 10.1164/rccm.2009-040GL.
  2. Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI: 10.1016/S22132600(14)70101-8.
  3. Manen M.J., Birring S.S., Vancheri C. et al. Cough in idiopathic pulmonary fibrosis. Eur. Respir. Rev.2016; 25 (141): 278–286. DOI: 10.1183/16000617.0090-2015.
  4. Yount S.E., Beaumont J.L., Chen S.Y. et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung. 2016; 194 (2): 227–234. DOI: 10.1007/s00408-0169850-y
  5. Ley B., Collard H.R., King T.E. Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2011; 183 (4): 431–440. DOI: 10.1164/rccm.201006-0894CI.
  6. Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI: 10.1164/rccm.201604-0801CI.
  7. Cottin V. The impact of emphysema in pulmonary fibrosis. Eur. Respir. Rev. 2013; 22 (128): 153–157. DOI: 10.1183/ 09059180.00000813.
  8. Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI: 10.1183/09031936.00217614.
  9. 1183/13993003.02316-2014. 10. Bonella F., Kreuter M., Hagmeyer L. et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016; 92 (2): 98–106. DOI: 10.1159/000448288.
  10. Maher R.L., Hanlon J., Hajjar E.R. Clinical consequences of polypharmacy in elderly.Exp. Opin. Drug Saf.2014; 13 (1): 57–65. DOI: 10.1517/14740338.2013.827660.
  11. Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242. DOI: 10.1056/NEJMoa 042976.
  12. Raghu G., Brown K.K., Costabel U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178 (9): 948–955. DOI: 10.1164/rccm.2007091446OC.
  13. King T.E. Jr, Albera C., Bradford W.Z. et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374 (9685): 222– 228. DOI: 10.1016/S0140-6736(09)60551-1.
  14. Daniels C.E., Lasky J.A., Limper A.H. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181 (6): 604–610. DOI: 10.1164/rccm.2009060964OC.
  15. Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2012; 186 (1): 88–95. DOI: 10.1164/rccm.201202-0314OC.
  16. King T.E. Jr, Behr J., Brown K.K. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med. 2008; 177 (1): 75–81. DOI: 10.1164/rccm.200705-732OC.
  17. King T.E. Jr, Brown K.K., Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med.2011; 184 (1): 92–99. DOI: 10.1164/rccm.201011-1874OC.
  18. Raghu G., Million-Rousseau R., Morganti A. et al. Macitentan for the reatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur. Respir. J. 2013; 42 (6): 1622–1632. DOI: 10.1183/09031936.00104612.
  19. Raghu G., Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.Ann. Intern. Med. 2013; 158 (9): 641–649. DOI: 10.7326/0003-4819-158-9-201305070-00003.
  20. Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.N. Engl. J. Med. 2014; 370 (22): 2093–2101. DOI: 10.1056/NEJMoa1401739.
  21. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 512Пульмонология. 2017; 27 (4): 502–514. DOI: 10.18093/08693018932017327343502–514 N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI: 10. 1056/NEJMoa1103690. 41. Yu Z.H., Wang D.D., Zhou Z.Y. et al. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol. Pharm. Bull.2012; 35 (5): 731–736. 42. Chen Y., Zhao M., Fu M. et al. The role of calcineurin in the lung fibroblasts proliferation and collagen synthesis induced by basic fibroblast growth factor. Chin. Med. J. (Engl.) 2003; 116 (6): 857–862. 43. Inoue Y., King T.E. Jr, Tinkle S.S
  22. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI: 10.1056/NEJMoa1402584.
  23. Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline.Am. J. Respir. Crit. Care Med.2015; 192 (2): e3–e19. DOI: 10.1164/rccm.201506-1063ST.
  24. Ahluwalia N., Shea B.S., Tager A.M. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Am. J. Respir. Crit. Care Med. 2014; 190 (8): 867–878. DOI: 10.1164/rccm.2014030509PP.
  25. Borensztajn K., Crestani B., Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers – insights from the bench side. Respiration. 2013; 86 (6): 441–452. DOI: 10.1159/000357598.
  26. Noble P.W., Barkauskas C.E., Jiang D. Pulmonary fibrosis: patterns and perpetrators. J. Clin. Invest. 2012; 122 (8): 2756–2762. DOI: 10.1172/JCI60323.
  27. Selman M., Pardo A. Revealing the pathogenic and agingrelated mechanisms of the enigmatic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2014; 189 (10): 1161–1172. DOI: 10.1164/rccm.201312-2221PP.
  28. Wuyts W.A., Agostini C., Antoniou K.M. et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur. Respir. J. 2013; 41 (5): 1207–1218. DOI: 10.1183/09031936.00073012.
  29. Fukihara J., Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.Exp. Rev. Respir. Med.2016; 10 (12): 1247–1254. DOI: 10.1080/17476348. 2016.1249854.
  30. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev.2004; 15 (4): 255–273. DOI: 10.1016/j.cytogfr.2004.03.006.
  31. Martinet Y., Rom W.N., Grotendorst G.R. et al. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1987; 317 (4): 202–209. DOI: 10.1056/NEJM198707233170404.
  32. Adamali H.I., Maher T.M. Current and novel drug therapies for idiopathic pulmonary fibrosis.Drug Des. Devel. Ther. 2012; 6: 261–272. DOI: 10.2147/DDDT.S29928.